ulricheasyINJECT Max 2M (XD 10140); ulricheasyINJECT Max 3 (XD 10150); ulricheasyINJECT Max 3 (XD 10180)

{0}------------------------------------------------ Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, with the letters "FDA" in a blue square. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue. April 19, 2024 ulrich GmbH & Co. KG % Rita King Chief Executive Officer MethodSense, Inc. 1 Copley Pkwy. Suite 130 Morrisville, North Carolina 27560 Re: K233737 Trade/Device Name: ulricheasyINJECT Max 2M (XD 10140); ulricheasyINJECT Max 3 (XD 10150); ulricheasyINJECT Max 3 (XD 10180) Regulation Number: 21 CFR 870.1650 Regulation Name: Angiographic injector and syringe Regulatory Class: Class II Product Code: IZQ Dated: November 21, 2023 Received: March 21, 2024 Dear Rita King: We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. {1}------------------------------------------------ Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download). Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30. Design controls; 21 CFR 820.90. Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181). Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems. For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). Sincerelv. Juliane C. Lessard -S Juliane C. Lessard, Ph.D. Director DHT3C: Division of Drug Delivery and General Hospital Devices, and Human Factors {2}------------------------------------------------ OHT3: Office of Gastrorenal, ObGyn, General Hospital, and Urology Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health Enclosure {3}------------------------------------------------ # Indications for Use 510(k) Number (if known) K233737 Device Name ulricheasyINJECT Max 2M (XD 10140); ulricheasyINJECT Max 3 (XD 10150): ulricheasyINJECT Max 3 (XD 10180) ### Indications for Use (Describe) Indications for Use - ulricheasyINJECT Max System (Max 2M (XD 10140) and Max 3 (XD 10150)) ulricheasylNJECT Max System Max 2M (XD 10140) and Max 3 (XD 10150) is a contrast media management system that is indicated for the controlled, automatic administration, on the venous side, of contrast media and saline (NaCl), to human subjects undergoing diagnostic examinations in magnetic resonance (MR) applications. ulricheasyINJECT Max 2M / 3 (XD 10140 / XD 10150) is specifically indicated for use in MRI procedures for the delivery of Clariscan (Gadoterate Meglumine) Injection, - GE Healthcare Inc. contrast media as supplied in approved single dose bottles. Easy-Click-Cassette – flex Max 2M and Easy-Click-Cassette – flex Max 3 are used for a maximum time of twenty four (24) hours or a maximum of 96 bottles of contrast media, or whichever comes first. Use time expiration per single dose contrast media container is a maximum of four (4) hours per contrast media container, unless otherwise stated by the contrast media labeling. Spike for MRI disposable is for single-bottle use only and must be discarded with the media container. The Patient tubing must be discarded after each patient procedure. ulricheasyINJECT Max is to be used only by and under quasi-continuous supervision of trained healthcare professionals in an appropriate licensed healthcare facility, in a room designated for radiological procedures that involve intravasular administration of contrast agent. The ulricheasyINJECT Max 2M / 3 (XD 10140 / XD 10150) is not intended for injection of contrast media (CM) for highpressure angiography. ### Indications for Use - ulricheasyINJECT Max 3 (XD 10180) ulricheasyINJECT Max 3 (XD 10180) is a contrast media management system that is indicated for the controlled, automatic administration, on the venous side, of contrast media and saline (NaCl), to human subjects undergoing diagnostic examinations in magnetic resonance (MR) applications. ulricheasyINJECT Max 3 (XD 10180) is specifically indicated for use in MRI procedures for the delivery of VUEWAY™ (gadopiclenol), - Bracco Diagnostics Inc, MultiHance (gadobenate dimeglumine) – Bracco Diagnostics, Inc, Clariscan™ (Gadoterate Meglumine) Injection, - GE Healthcare Inc., Dotarem® (gadoterate meglumine) Injection - Guerbet, LLC, and Gadavist™ (gadobutrol) Injection, - Bayer HealthCare Pharmaceuticals Inc., contrast media as supplied in approved single dose vials. Easy-Click-Cassette - flex Max 3 is used for a maximum time of twenty four (24) hours or a maximum of 96 bottles of contrast media, or whichever comes first. Use time expiration per single dose contrast is a maximum of four (4) hours per contrast media container, unless otherwise stated by the contrast media labeling. Spike for MRI disposable is for single-bottle use only and must be discarded with the media container. The Patient tubing must be discarded after each patient procedure. {4}------------------------------------------------ ulricheasylNJECT Max 3 (XD 10180) is to be used only by and under quasi-continuous supervision of trained healthcare professionals in an appropriate licensed healthcare facility, in a room designated for radiological procedures that involve intravascular administration of contrast agent. The ulricheasyINJECT Max 3 (XD 10180) is not intended for injection of contrast media (CM) for high-pressure angiography. Type of Use (Select one or both, as applicable) X Prescription Use (Part 21 CFR 801 Subpart D) Over-The-Counter Use (21 CFR 801 Subpart C) ### CONTINUE ON A SEPARATE PAGE IF NEEDED. This section applies only to requirements of the Paperwork Reduction Act of 1995. ### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.* The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: > Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number." {5}------------------------------------------------ ## Summary of 510(k) ### Ulrich GmbH & Co. KG K233737 This 510(k) Summary is in conformance with 21CFR 807.92 | Submitter: | ulrich GmbH & Co. KG<br>Buchbrunnenweg 12<br>89081 Ulm<br>Germany<br>Phone: +49 731 9654-1714<br>Fax: +49 731 9654-2807 | |------------------|-------------------------------------------------------------------------------------------------------------------------| | Primary Contact: | Rita King, CEO<br>MethodSense, Inc.<br>Email: ritaking@methodsense.com<br>Phone: 919-313-3961<br>Fax: 919-313-3979 | | Company Contact: | Sven Erdmann<br>Vice President of Technology - Regulatory | | Device Name and Classification | | |--------------------------------|----------------------------------------------------| | Trade Name: | ulricheasyINJECT Max | | Common Name: | Contrast Media Management System | | Classification: | Class II | | Regulation Number: | 21 CFR 870.1650, Angiographic Injector and Syringe | | Classification Panel: | Cardiovascular Panel | | Product Code: | IZQ | ### Predicate Device: | | Predicate | |---------------------------|----------------------------------------------------| | Trade Name | ulrichINJECT CT motion | | Common Name | Contrast Media Management System | | 510(k) Submitter / Holder | Class II | | 510(k) Number | K192872 | | Regulation Number | 21 CFR 870.1650, Angiographic Injector and Syringe | | Classification Panel | Cardiovascular Panel | | Product Code | IZQ | The predicate device has not been subject to a design-related recall. ### Device Description ulricheasyINJECT Max is a syringeless contrast media management system that is designed for the controlled, automatic venous administration of contrast media in conjunction with physiological saline solution to human subjects underqoing diagnostic examinations in Magnetic Resonance Imaging (MRI or PET MRI). The ulricheasyINJECT Max device consists of a terminal, injector, and tubing system. The injector is a mobile pedestal device that consists of an injector base with rechargeable battery. The tubing system is the only component that comes in contact with the patient and has indirect contact with the blood path of a patient for a limited duration (few minutes). The tubing system consists of the following three components: - . Spikes, {6}------------------------------------------------ - . Easy-Click-Cassette - flex - . Patient Tubing The ulricheasyINJECT Max uses a peristaltic pump as part of the injector which is designed to transport the media fluid through the tubing system (spikes, cassette, and patient tubing), ulricheasylNJECT Max is intended to be used with the following components that are not supplied with the system: - Saline containers, - Single-dose contrast media bottles, and . - . Cannula. ulricheasylNJECT Max is equipped with multiple hardware and software controls that work together for the safe operation of the intended use of the system. Controls include air detect the presence of air in the tubing system without direct contact with the medium, pressure controls to manage and regulate pressure inside the tubing system, and check valves to prevent backflow of media and avoid retrograde contamination. The ulricheasyINJECT Max is provided in three models: - . ulricheasyINJECT Max 2M (XD 10140), - . ulricheasyINJECT Max 3 (XD 10150), and - . ulricheasyINJECT Max 3 (XD 10180). The Max 3 models have 3 media connection points: 1 NaCl and 2 Contrast Media connections. The Max 2M has 2 media connection points: 1 NaCl and 1 Contrast Media connections. Max 2M and Max 3 are technically identical except the different available media connection points. ### Indications for Use ### Indications for Use – ulricheasyINJECT Max System (Max 2M (XD 10140) and Max 3 (XD 10150)) ulricheasyINJECT Max System Max 2M (XD 10140) and Max 3 (XD 10150) is a contrast media management system that is indicated for the controlled, automatic administration, on the venous side, of contrast media and saline (NaCI), to human subjects undergoing diagnostic examinations in magnetic resonance (MR) applications. ulricheasylNJECT Max 2M / 3 (XD 10140 / XD 10150) is specifically indicated for use in MRI procedures for the delivery of Clariscan (Gadoterate Meglumine) Injection, - GE Healthcare Inc. contrast media as supplied in approved single dose bottles. Easy-Click-Cassette - flex Max 2M and Easy-Click-Cassette - flex Max 3 are used for a maximum time of twenty four (24) hours or a maximum of 96 bottles of contrast media, or whichever comes first. Use time expiration per single dose contrast media container is a maximum of four (4) hours per contrast media container, unless otherwise stated by the contrast media labeling. Spike for MRI disposable is for single-bottle use only and must be discarded with the media container. The Patient tubing must be discarded after each patient procedure. ulricheasyINJECT Max is to be used only by and under quasi-continuous supervision of trained healthcare professionals in an appropriate licensed healthcare facility, in a room designated for radiological procedures that involve intravascular administration of contrast agent. The ulricheasyINJECT Max 2M / 3 (XD 10140 / XD 10150) is not intended for injection of contrast media (CM) for high-pressure angiography. Indications for Use – ulricheasyINJECT Max 3 (XD 10180) {7}------------------------------------------------ ulricheasylNJECT Max 3 (XD 10180) is a contrast media management system that is indicated for the controlled, automatic administration, on the venous side, of contrast media and saline (NaCI), to human subjects undergoing diagnostic examinations in magnetic resonance (MR) applications. ulricheasylNJECT Max 3 (XD 10180) is specifically indicated for use in MRI procedures for the delivery of VUEWAY™ (qadopiclenol), - Bracco Diagnostics Inc. MultiHance (gadobenate dimeqlumine) - Bracco Diagnostics, Inc, Clariscan™ (Gadoterate Meglumine) Injection, - GE Healthcare Inc., Dotarem® (gadoterate meglumine) Injection – Guerbet, LLC, and Gadavist™ (gadobutrol) Injection, - Bayer HealthCare Pharmaceuticals Inc., contrast media as supplied in approved single dose vials. Easy-Click-Cassette - flex Max 3 is used for a maximum time of twenty four (24) hours or a maximum of 96 bottles of contrast media, or whichever comes first. Use time expiration per single dose contrast media container is a maximum of four (4) hours per contrast media container, unless otherwise stated by the contrast media labeling. Spike for MRI disposable is for single-bottle use only and must be discarded with the media container. The Patient tubing must be discarded after each patient procedure. ulricheasyINJECT Max 3 (XD 10180) is to be used only by and under quasi-continuous supervision of trained healthcare professionals in an appropriate licensed healthcare facility, in a room designated for radiological procedures that involve intravascular administration of contrast agent. The ulricheasyINJECT Max 3 (XD 10180) is not intended for injection of contrast media (CM) for highpressure angiography. ## Predicate Device Comparison ulricheasyINJECT Max is substantially equivalent to the ulrichINJECT CT Motion (K192872) by ulrich GmbH & Co. KG that is currently on the market. {8}------------------------------------------------ # Comparative Analysis of the ulricheasyINJECT Max to the Predicate Device | Characteristic | Subject Device<br>ulricheasyINJECT Max<br>(XD 10140 / XD 10150 / XD 10180)<br>(K233737) | Predicate Device<br>ulrichINJECT CT motion<br>(K192872) | Comparison | |-------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | Intended Use | ulricheasyINJECT Max 2M (XD 10140) / 3 (XD<br>10150 / XD 10180) is a contrast media<br>management system that is indicated for the<br>controlled, automatic administration, on the<br>venous side, of contrast media and saline<br>(NaCl), to human subjects undergoing<br>diagnostic examinations | ulrichINJECT CT motion is a contrast media<br>management system that is intended for the<br>controlled, automatic administration, on the<br>venous side, of contrast media and saline<br>(NaCl), to human subjects undergoing<br>diagnostic examinations | Same | | Indications for Use | ulricheasyINJECT Max 2M (XD 10140) / 3 (XD<br>10150)<br>ulricheasyINJECT Max 2M (XD 10140) / 3 (XD<br>10150) is a contrast media management<br>system that is indicated for the controlled,<br>automatic administration, on the venous side, of<br>contrast media and saline (NaCl), to human<br>subjects undergoing diagnostic examinations in<br>magnetic resonance (MR) applications.<br>ulricheasyINJECT Max 2M / 3 (XD 10140 / XD<br>10150) is specifically indicated for use in MRI<br>procedures for the delivery of Clariscan<br>(Gadoterate Meglumine) Injection, - GE<br>Healthcare Inc. contrast media as supplied in<br>approved single dose bottles.<br>Easy-Click-Cassette - flex Max 2M and Easy-<br>Click-Cassette – flex Max 3 are used for a<br>maximum time of twenty four (24) hours or a<br>maximum of 96 bottles of contrast media, or<br>whichever comes first. Use time expiration per<br>single dose contrast media container is a<br>maximum of four (4) hours per contrast media<br>container, unless otherwise stated by the<br>contrast media labeling.<br>Spike for MRI disposable is for single-bottle use<br>only and must be discarded with the media | ulrichINJECT CT motion is a contrast media<br>management system that is indicated for the<br>controlled, automatic administration, on the<br>venous side, of contrast media and saline<br>(NaCl), to human subjects undergoing<br>diagnostic examinations in computed<br>tomography (CT) applications.<br>ulrichINJECT CT motion is specifically<br>indicated for use in CT procedures for the<br>delivery of Omnipaque™ (Iohexol) Injection,<br>solution - GE Healthcare Inc. contrast media<br>as supplied in Imaging Bulk Packages (IBP),<br>Omnipaque™ (Iohexol) Injection, solution - GE<br>Healthcare Inc., and Visipaque™ (iodixanol)<br>Injection - GE Healthcare Inc. contrast media<br>as supplied in single dose bottles.<br>Pump tubing-flex is used for a maximum time<br>of twenty four (24) hours. When used with<br>Omnipaque™ IBP, Omnipaque™ single dose<br>bottles, or Visipaque™ single dose bottles, a<br>maximum of 19 bottles of contrast media can<br>be used or maximum time of twenty four (24)<br>hours of Pump tubing-flex, or whichever<br>comes first. Time per contrast media or saline<br>container depends on each contrast media's<br>or saline's use time expiration with a maximum | Different - This difference does not<br>change the intended use of the<br>device. The safety and effectiveness<br>of the ulricheasyINJECT Max has<br>been confirmed through MR<br>compatibility testing, chemical<br>compatibility testing, and Safety /<br>EMC testing. | | Characteristic | Subject Device | Predicate Device | Comparison | | | ulricheasyINJECT Max<br>(XD 10140 / XD 10150 / XD 10180) | ulrichINJECT CT motion<br>(K192872) | | | | (K233737) | | | | | container. The Patient tubing must be | of eight (8) hours per contrast media or saline | | | | discarded after each patient procedure. | container. | | | | ulricheasyINJECT Max 2M / 3 (XD 10140 / XD<br>10150) is to be used only by and under quasi-<br>continuous supervision of trained healthcare<br>professionals in an appropriate licensed<br>healthcare facility, in a room designated for<br>radiological procedures that involve<br>intravascular administration of contrast agent.<br>The ulricheasyINJECT Max 2M / 3 (XD 10140 /<br>XD 10150) is not intended for injection of<br>contrast media (CM) for high-pressure<br>angiography. | Spike for CT disposable is for single-bottle use<br>only and must be discarded with the media<br>container. The Patient tubing must be<br>discarded after each patient procedure.<br>ulrichINJECT CT motion is to be used only by<br>and under quasi-continuous supervision of<br>trained healthcare professionals in an<br>appropriate licensed healthcare facility, in a<br>room designated for radiological procedures<br>that involve intravascular administration of<br>contrast agent. | | | | ulricheasyINJECT Max 3 (XD 10180)<br>ulricheasyINJECT Max 3 (XD 10180) is a<br>contrast media management system that is<br>indicated for the controlled, automatic<br>administration, on the venous side, of contrast<br>media and saline (NaCl), to human subjects<br>undergoing diagnostic examinations in<br>magnetic resonance (MR) applications. | | | | | ulricheasyINJECT Max 3 (XD 10180) is<br>specifically indicated for use in MRI procedures<br>for the delivery of VUEWAY™ (gadopiclenol)<br>Injection - Bracco Diagnostics, Inc., MultiHance<br>(gadobenate dimeglumine) - Bracco<br>Diagnostics, Inc, Clariscan™ (Gadoterate<br>Meglumine) Injection, - GE Healthcare Inc.,<br>Dotarem® (gadoterate meglumine) Injection -<br>Guerbet, LLC, and Gadavist™ (gadobutrol)<br>Injection, - Bayer HealthCare Pharmaceuticals<br>Inc., contrast media as supplied in approved<br>single dose vials. | | | | | Easy-Click-Cassette - flex Max 3 is used for a<br>maximum time of twenty four (24) hours or a<br>maximum of 96 bottles of contrast media, or | | | | Characteristic | Subject Device<br>ulricheasyINJECT Max<br>(XD 10140 / XD 10150 / XD 10180)<br>(K233737) | Predicate Device<br>ulrichINJECT CT motion<br>(K192872) | Comparison | | | whichever comes first. Use time expiration per<br>single dose contrast media container is a<br>maximum of four (4) hours per contrast media<br>container, unless otherwise stated by the<br>contrast media labeling.<br>Spike for MRI disposable is for single-bottle use<br>only and must be discarded with the media<br>container. The Patient tubing must be<br>discarded after each patient procedure.<br>ulricheasyINJECT Max 3 (XD 10180) is to be<br>used only by and under quasi-continuous<br>supervision of trained healthcare professionals<br>in an appropriate licensed healthcare facility, in<br>a room designated for radiological procedures<br>that involve intravascular administration of<br>contrast agent. | | | | | The ulricheasyINJECT Max 3 (XD 10180) is<br>not intended for injection of contrast media<br>(CM) for high-pressure angiography. | | | | Product Codes | | | | | Product Codes | IZQ<br>(21 CFR 870.1650) | IZQ<br>(21 CFR 870.1650) | Same | | Device Use | | | | | Environment of<br>Use | MR Environment | CT Environment | Different - This difference does not<br>change the intended use of the<br>device. The safety and effectiveness<br>of the ulricheasyINJECT Max has<br>been confirmed through MR<br>compatibility testing, chemical<br>compatibility testing, and Safety /<br>EMC testing. | | Physical | | | | | System | Injector Head<br>Touch Terminal | Injector Head<br>Touch Terminal | Same | | Characteristic | Subject Device<br>ulricheasyINJECT Max<br>(XD 10140 / XD 10150 / XD 10180)<br>(K233737) | Predicate Device<br>ulrichINJECT CT motion<br>(K192872)…